Back to Search
Start Over
First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
- Source :
- Retrovirology, Retrovirology, Vol 9, Iss Suppl 2, p P134 (2012)
- Publisher :
- Springer Nature
-
Abstract
- Methods HVTN 090 enrolled sixty healthy, HIV-1-uninfected adults in a randomized, double-blinded, placebo-controlled dose escalation study. Groups of 12 participants received rVSV Indiana HIV Gag vaccine at 5 dose levels (4.6 x 10 to 3.4 x 10 PFU) (N=10/group) or placebo (N=2/group), delivered intramuscularly at 0 and 2 months. Reactogenicity over 7 days, adverse events (AEs), and viral cultures from whole blood, urine, saliva and swabs of oral lesions were collected. HIV-1-specific CD4+ and CD8+ T-cell responses to Gag peptides were measured 1 and 2 weeks post-boost by intracellular cytokine staining.
- Subjects :
- lcsh:Immunologic diseases. Allergy
Saliva
Reactogenicity
biology
business.industry
Phases of clinical research
Bioinformatics
Placebo
biology.organism_classification
Virology
chemistry.chemical_compound
Infectious Diseases
chemistry
Vesicular stomatitis virus
Poster Presentation
Medicine
Vaccinia
lcsh:RC581-607
business
Adverse effect
Whole blood
Subjects
Details
- Language :
- English
- ISSN :
- 17424690
- Volume :
- 9
- Issue :
- Suppl 2
- Database :
- OpenAIRE
- Journal :
- Retrovirology
- Accession number :
- edsair.doi.dedup.....13d443391d01082a78237e92e05e44c4
- Full Text :
- https://doi.org/10.1186/1742-4690-9-s2-p134